AtriCure (ATRC)

• Market cap: $1.87B
• 1 day: -1.97%
• 5 days: -3.57%
• 1 month: -3.13%
• 3 months: 7.60%
• 6 months: 60.03%
• Year to date: 26.28%
• 1 year: 16.23%
• 5 years: -2.59%
• 10 years: 110.82%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Employees: 1,200

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

806% more call options, than puts

Call options by funds: $1.25M | Put options by funds: $138K

74% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 23

6% more funds holding

Funds holding: 199 [Q3] → 210 (+11) [Q4]

2% more capital invested

Capital invested by funds: $1.39B [Q3] → $1.42B (+$29.2M) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 73

6.49% less ownership

Funds ownership: 101.53% [Q3] → 95.05% (-6.49%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 17% upside
• Avg. target: $53 38% upside
• High target: $66 72% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Suraj Kalia 67% 1-year accuracy 16 / 24 met price target	17% upside $45	Outperform Maintained	13 Feb 2025
Piper Sandler Matt O'Brien 64% 1-year accuracy 35 / 55 met price target	30% upside $50	Overweight Maintained	13 Feb 2025
JMP Securities Daniel Stauder 67% 1-year accuracy 4 / 6 met price target	56% upside $60	Market Outperform Reiterated	13 Feb 2025
Stifel Rick Wise 64% 1-year accuracy 21 / 33 met price target	25% upside $48	Buy Maintained	13 Feb 2025
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target	33% upside $51	Buy Reiterated	13 Feb 2025